TUBB3

Tubulin beta-3 chain

Score: 0.584 Price: $0.58 Medium Druggability Status: active Wiki: TUBB3

🧠 Neurodegeneration

HYPOTHESES

1

PAPERS

32

KG EDGES

213

DEBATES

1

3D Protein Structure

🧬 TUBB3 — PDB 5CA1 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Medium

Score: 0.49

Clinical Stage

Approved

Target Class

Structural Protein

Safety

0.30

Druggability Analysis

Drug Development1.00

Structural Tractability0.85

Target Class0.50

Safety Profile0.30

Key Metrics

PDB Structures:

25

Known Drugs:

3

Approved:

3

In Clinical Trials:

0

Drug Pipeline (3 compounds)

3 Approved

Druggability Rationale: TUBB3 exhibits high druggability (0.90 score) due to extensive structural characterization (25 PDB structures, 1.8Å resolution), a well-defined microtubule binding pocket validated by three approved taxane drugs, and the target's role as a structural protein with established small-molecule stabilizer mechanisms. The availability of cryo-EM data and AlphaFold models further supports rational drug design and optimization.

Mechanism: Small molecule stabilizers of microtubule structure or assembly

Drug Pipeline (3 compounds)

3 Approved

Known Drugs:

Paclitaxel (approved) — Cancer

Docetaxel (approved) — Cancer

Cabazitaxel (approved) — Cancer

Structural Data:

PDB (25) ✓AlphaFold ✓Cryo-EM ✓

22AJ 22AK 5IJ0 5IJ9 5JCO+20 more

UniProt: G3V3R4

🧬 3D Protein Structure

🧬 TUBB3 — PDB 5CA1 Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

Selectivity remains a significant challenge given TUBB3's structural similarity to other β-tubulin isoforms (TUBB, TUBB2A, TUBB2B); achieving isoform-selective inhibition is difficult and off-target effects on ubiquitous tubulin isoforms may limit neurological applications. However, TUBB3's neuron-specific expression provides a therapeutic window for CNS-focused development over peripheral tissues.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

4

Completed

4

Total Enrollment

3,844

By Phase

PHASE1: 1 · PHASE2: 4 · PHASE3: 3

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to C Recruiting

PHASE3 NCT06470243 n=528

Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8

Interventions: Biospecimen Collection, Bone Scan, Cabazitaxel

Sponsor: SWOG Cancer Research Network | Started: 2024-11-27

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage III Recruiting

PHASE1 NCT05819892 n=21

Endometrial Cancer

Interventions: Paclitaxel, Carboplatin, Dostarlimab

Sponsor: M.D. Anderson Cancer Center | Started: 2023-07-17

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Ca Not Yet Recruiting

PHASE2 NCT07432594 n=82

High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers, Primary Peritoneal Cancer

Interventions: Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5)

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sc | Started: 2026-03-01

Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Asses Not Yet Recruiting

PHASE2 NCT04622761 n=120

Prostate Cancer

Interventions: Cabazitaxel

Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust | Started: 2021-01-15

A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer Completed

PHASE3 NCT03705429 n=51

Breast Neoplasms

Interventions: TC-H x Paclitaxel (P) + Trastuzumab(T)

Sponsor: London Health Sciences Centre Research Institute OR Lawson R | Started: 2019-05-01

A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (G Completed

PHASE3 NCT00196872 n=3000

Breast Cancer

Interventions: Epirubicine, Cyclophosphamide, Taxol

Sponsor: GBG Forschungs GmbH | Started: 2004-07

Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed

PHASE2 NCT00511992 n=20

Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma, Ovarian Carcinosarcoma

Interventions: Avastin, Paclitaxel, Cisplatin

Sponsor: University of Oklahoma | Started: 2007-07

GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer Completed

PHASE2 NCT00087165 n=22

Prostate Cancer

Interventions: GTI-2040, docetaxel, prednisone

Sponsor: University Health Network, Toronto | Started: 2005-01

Linked Hypotheses (1)

Quantum Coherence Disruption in Cellular Communication0.627

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

associated with (6)

TUBB3→neurodegenerationSQSTM1→TUBB3TUBB3→STK11TUBB3→VIMTUBB3→HDAC6

▸ Show 1 more

TUBB3→MAP1LC3B

co discussed (7)

BMAL1→TUBB3CNO→TUBB3TUBB3→CLOCKTUBB3→PLIN2TUBB3→PIEZO1

▸ Show 2 more

TUBB3→GABRA1TUBB3→G3BP1

inhibits (1)

regulates (5)

ACTB→TUBB3CDC42→TUBB3CASP3→TUBB3TUBB3→BECN1TUBB3→GAPDH

therapeutic target (1)

Debate History (1)

Should TUBB3 (Tubulin beta-3 chain) be prioritized as a therapeutic target for n2026-04-21